<DOC DOCNO="nw/xinhua/00/chtb_0064@0064@xinhua@nw@en@on">
<TEXT PARTNO="000">
<COREF ID="10498" TYPE="IDENT"><COREF ID="10499" TYPE="APPOS" SUBTYPE="HEAD">Huiliang Bai</COREF> , <COREF ID="10499" TYPE="APPOS" SUBTYPE="ATTRIB">director of the National Pharmaceutical Management Bureau Office</COREF></COREF> says that the areas of pharmaceutical industry in which <COREF ID="10507" TYPE="IDENT">China</COREF> encourages foreign businesses *PRO*-1 to invest *T*-15 are : those that *T*-16 can meet the needs of domestic and foreign markets , upgrade product levels , expand foreign sales , increase exports and foreign currency earnings ; enterprises that *T*-17 can produce medicine that *T*-18 can not be produced *-18 by <COREF ID="10507" TYPE="IDENT">China</COREF> but is urgently needed ; those that *T*-20 can introduce domestically needed advanced technology *PRO* to reform old enterprises ; those that *T*-21 can introduce new high level technology , patent technology and products ; and those that *T*-22 bring advanced management experience .
<COREF ID="10498" TYPE="IDENT">He</COREF> says that apart from investment , <COREF ID="10507" TYPE="IDENT">the Chinese government</COREF> also welcomes cooperation of foreign pharmaceutical enterprises *PRO* to cooperate with <COREF ID="10507" TYPE="IDENT">China</COREF> in other ways , such as compensation trade , licensing trade , third party processing , technology transfer , and joint development of new products .
-LRB- End -RRB-
</TEXT>
</DOC>
